Abstract: The present disclosure provides monoclonal antibodies (e.g., anti-TNF? antibodies) having Fab sialylation, and, in some aspects, Fab sialylation in combination with an afucosylated Fc. Such antibodies having improved immunogenicity profiles and related advantages. Such glycan modifications will improve current treatments and allow a better quality of life for patients. Accordingly, such monoclonal antibodies are useful for treating and preventing various diseases.

Abstract: The invention relates to an arrangement of several layers of catalysts arranged in series in a reactor for the hydroisomerisation of hydrocarbons, to a method for the hydroisomerisation of hydrocarbons and to the use of the arrangement for the hydroimerisation of hydrocarbons.

Abstract: Method for replacing, inspecting, and/or repairing components in front bearing region of gas turbine, the gas turbine having at least one fan module, housing, low-pressure system, and high-pressure system, the low-pressure system having low-pressure compressor, low-pressure turbine, connecting shaft, stub shaft, and an N1 shaft connected to the low-pressure compressor via the stub shaft and the connecting shaft, the connecting shaft supported in the housing via first bearing unit, and the stub shaft supported in the housing via second bearing unit, the method including dismounting the fan module, fixing the N1 shaft in an axial direction relative to the housing using fixing device, and dismounting the stub shaft using guide device, the orientation of which relative to the gas turbine in at least one spatial direction is determined by a component of the remaining gas turbine, this taking place after fixing the N1 shaft and after dismounting the fan module.

Abstract: This invention relates to a process for producing aluminum silicates in the form of zeolite L, as well as the intermediate and end products of this process. The invention further relates to the use of these aluminum silicates for the conversion or adsorption of hydrocarbons.

Abstract: Disassembly method for gas turbines (11) for replacing and/or inspecting and/or repairing components arranged in a front bearing region (5) of the gas turbine (11), the gas turbine (11) comprising at least one fan module (1), a gas turbine housing, a low-pressure system and a high-pressure system, the low-pressure system comprising a low-pressure compressor (4), a low-pressure turbine (9), a connecting shaft (13), a stub shaft (8) and an N1 shaft (10), the N1 shaft (10) being connected to the low-pressure compressor (4) via the stub shaft (8) and the connecting shaft (1), the connecting shaft (13) being supported in the gas turbine housing via a first bearing unit (6), and the stub shaft (8) being supported in the gas turbine housing via a second bearing unit (7), wherein the disassembly method comprises at least the steps of: a) dismounting the fan module (1), and b) fixing the N1 shaft (10) in an axial direction relative to the gas turbine housing using a fixing device (14), and c) dismounting the stub

Abstract: The invention provides cyclo[{4-(NH2—C2H4—NH—CO—O—)Pro}-Phg-DTrp-Lys-Tyr(4-Benzyl)-Phe], optionally in protected form, or a pharmaceutically acceptable salt or complex thereof, which has interesting pharmaceutical properties.

Abstract: The invention provides cyclo[{4-(NH2—C2H4—NH—CO—O—)Pro}-Phg-DTrp-Lys-Tyr(4-Benzyl)-Phe], optionally in protected form, or a pharmaceutically acceptable salt or complex thereof, which has interesting pharmaceutical properties.

Abstract: The invention provides cyclo[{4-(NH2—C2H4—NH—CO—O-)Pro}-Phg-DTrp-Lys-Tyr(4-Benzyl)-Phe], optionally in protected form, or a pharmaceutically acceptable salt or complex thereof, which has interesting pharmaceutical properties.

Abstract: This invention relates to a process for producing aluminium silicates in the form of zeolite L, as well as the intermediate and end products of this process. The invention further relates to the use of these aluminium silicates for the conversion or adsorption of hydrocarbons.

Abstract: Compounds of formula I: wherein R1, R2, n and m are as defined in the specification, processes for their production, their uses and pharmaceutical compositions containing them.

Abstract: The invention provides cyclo[{4-(NH2—C2H4—NH—CO—O—)Pro}-Phg-DTrp-Lys-Tyr(4-Benzyl)-Phe], optionally in protected form, or a pharmaceutically acceptable salt or complex thereof, which has interesting pharmaceutical properties.

Abstract: The invention provides cyclo[{4-(NH2—C2H4—NH—CO—O—)Pro}-Phg-DTrp-Lys-Tyr(4-Benzyl)-Phe], optionally in protected form, or a pharmaceutically acceptable salt or complex thereof, which has interesting pharmaceutical properties.

Abstract: Compounds of formula I: wherein R1, R2, n and m are as defined in the specification, processes for their production, their uses and pharmaceutical compositions containing them.

Abstract: The invention provides cyclo[{4-(NH2—C2H4—NH—CO—O—)Pro}-Phg-DTrp-Lys-Tyr(4-Benzyl)-Phe], optionally in protected form, or a pharmaceutically acceptable salt or complex thereof, which has interesting pharmaceutical properties.

Abstract: Compounds of formula I: wherein R1, R2, n and m are as defined in the specification, processes for their production, their uses and pharmaceutical compositions containing them.

Abstract: Indolylmaleimide derivatives comprising either a substituted phenyl, naphthyl, tetrahydronaphthyl, quinazolinyl, quinolyl, isoquinolyl or pyrimidinyl residue have interesting pharmaceutical properties, e.g. in the treatment and/or prevention of T-cell mediated acute or chronic inflammatory diseases or disorders, autoimmune diseases, graft rejection or cancer.

Abstract: Compounds of formula I, wherein X, a, b, R1, R2, R3, R4 and R5 are as defined in the specification, processes for their production, their uses and pharmaceutical compositions containing them.

Abstract: Novel organic compounds are described and claimed which may in particular be useful in the treatment of diseases being triggered by the (human) autoimmune system.

Abstract: The present invention relates to polycyclic compounds, processes for their production, their use as pharmaceuticals and to pharmaceutical compositions comprising them.

Abstract: Indolylmaleimide derivatives comprising either a substituted phenyl, naphthyl, tetrahydronaphthyl, quinazolinyl, quinolyl, isoquinolyl or pyrimidinyl residue have interesting pharmaceutical properties, e.g. in the treatment and/or prevention of T-cell mediated acute or chronic inflammatory diseases or disorders, autoimmune diseases, graft rejection or cancer.